McDermott Will & Emery represented Inhibikase Therapeutics, Inc. in the transaction. Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
Inhibikase Therapeutics’ $10 Million Direct Offering and Private Placements
Portage Biotech’s Acquisition of Tarus Therapeutics
McDermott Will and Emery represented Portage Biotech Inc. in the transaction. Portage Biotech Inc., a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase...